THERAPY DOSSIER · th-f432d4d08746

Ganoderic acid A, a triterpenoid from Ganoderma, purity greater than 96%

Nutraceutical · Ganoderic acid A, a Ganoderma triterpenoid.

Evidence & regulatory context

Mechanism: Ganoderic acid A, a Ganoderma triterpenoid.
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31072918 ↗2019Reported benefit

Ganoderic acid A attenuates lipopolysaccharide-induced lung injury in mice.

MouseEndotoxin/LPSBALB/cMalen = Ten mice per group at randomisation across five groups; n=8…Intraperitoneal10 and 20 mg/kg as stated in the Methods; the Figure 5 lege…One hour before intratracheal lipopolysaccharide

Model: Acute lung injury induced by intratracheal instillation of lipopolysaccharide, 20 micrograms at 0.4 micrograms per microlitre

Ganoderic acid A lowered the lung wet-to-dry weight ratio, reduced myeloperoxidase activity and malondialdehyde, raised superoxide dismutase activity, reduced TNF-alpha, IL-1beta and IL-6 in lavage fluid and lessened neutrophil infiltration on histology. These effects were accompanied by suppressio…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…